Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | ACE | P12821 | 2/20 | 0.37 |
| ▸ | PRCP | P42785 | 1/20 | 0.36 |
| ▸ | DRD3 | P35462 | 1/20 | 0.36 |
| ▸ | DPP8 | Q6V1X1 | 2/20 | 0.36 |
| ▸ | DPP9 | Q86TI2 | 2/20 | 0.36 |
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.36 |
| ▸ | DPP4 | P27487 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | BRS3 | P32247 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12658784 | 1.00 | MEN1 (0.38) | MEN1KMT2AACEPRCPDRD3 | |
| SCHEMBL12658781 | 1.00 | MEN1 (0.38) | MEN1KMT2AACEPRCPDRD3 | |
| SCHEMBL6369694 | 0.77 | PRCP (0.39) | PRCPDRD3KDM4ENPC1RAB9A | |
| SCHEMBL13416638 | 0.77 | MAOA (0.39) | MEN1KMT2AACE | |
| SCHEMBL12650870 | 0.77 | MAOA (0.39) | MEN1KMT2AACE | |
| SCHEMBL4737676 | 0.75 | MEN1 (0.36) | MEN1KMT2AACE | |
| SCHEMBL13247993 | 0.75 | MEN1 (0.36) | MEN1KMT2AACE | |
| SCHEMBL6370468 | 0.75 | PRCP (0.38) | PRCPDRD3KDM4ENPC1RAB9A | |
| SCHEMBL19368950 | 0.73 | ACE (0.47) | ACEDPP8DPP9DPP7DPP4 | |
| SCHEMBL6369819 | 0.72 | BCL2 (0.38) | PRCPDRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7947256-B2 | Biocompatible fluorescent imaging agents | VISEN MEDICAL, INC. (US) | 2011-05-24 | — | — | US | disclosed |
| US-20080317676-A1 | Biocompatible Fluorescent Imaging Agents | VISEN MEDICAL, INC. | 2008-12-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080317676-A1 | Biocompatible Fluorescent Imaging Agents | CD47, FIBP, CD68 | MEN1 1115/4885KMT2A 4157/4885ACE 4166/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.